{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:05:08Z","timestamp":1791385508724,"version":"4.3.3"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ijantimicag.2017.05.013","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T19:30:14Z","timestamp":1498591814000},"page":"115-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Dosing of caspofungin based on a pharmacokinetic\/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration"],"prefix":"10.1016","volume":"51","author":[{"given":"Alejandro","family":"P\u00e9rez-Pitarch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Ferriols-Lisart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Ezquer-Gar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Javier","family":"Belda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Guglieri-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 7","key":"10.1016\/j.ijantimicag.2017.05.013_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non\u2013neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0015","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/cid\/civ1194","article-title":"Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0020","series-title":"Cancidas: Summary of product characteristics","author":"EMA","year":"2015"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0025","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/QCO.0000000000000111","article-title":"Echinocandin resistance: an emerging clinical problem?","volume":"27","author":"Arendrup","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0030","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1128\/AAC.00019-12","article-title":"Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia","volume":"56","author":"Shah","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0035","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/QCO.0b013e3282f1bea3","article-title":"Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies","volume":"20","author":"Gumbo","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2011.07.013","article-title":"Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review","volume":"39","author":"Sinnollareddy","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0045","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/cc13803","article-title":"Treatment with echinocandins during continuous renal replacement therapy","volume":"18","author":"Gonzalez de Molina","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0050","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1128\/AAC.00335-13","article-title":"Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy","volume":"57","author":"Weiler","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13054-016-1594-9","article-title":"Optimal doses of caspofungin during continuous venovenous hemodiafiltration in critically ill patients","volume":"21","author":"Aguilar","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0060","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0065","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1128\/AAC.05134-11","article-title":"Phase II dose escalation study of caspofungin for invasive Aspergillosis","volume":"55","author":"Cornely","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0070","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.01912-12","article-title":"Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis","volume":"57","author":"Wurthwein","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0075","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/jac\/dkq081","article-title":"Echinocandin pharmacodynamics: review and clinical implications","volume":"65","author":"Pound","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0080","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0085","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1128\/AAC.01160-06","article-title":"Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species","volume":"51","author":"Antachopoulos","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0090","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0003-2670(97)00263-8","article-title":"Determination of cyclic hexapeptide (L-743872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection","volume":"352","author":"Schwartz","year":"1997","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0095","series-title":"Guideline on Bioanalytical Method Validation","author":"EMA","year":"2011"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0100","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/jac\/dkt542","article-title":"Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration","volume":"69","author":"Aguilar","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0105","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jac\/dkq545","article-title":"Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration","volume":"66","author":"Leitner","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0110","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1093\/jac\/dku313","article-title":"Pharmacokinetics of caspofungin in ICU patients","volume":"69","author":"Muilwijk","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0115","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40262-015-0347-2","article-title":"Dose Reduction of caspofungin in intensive care unit patients with Child Pugh B will result in suboptimal exposure","volume":"55","author":"Martial","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01582-16","article-title":"Low caspofungin exposure in patients in the intensive care unit","volume":"61","author":"van der Elst","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0125","series-title":"Cancidas: Scientific Discussion","author":"EMA","year":"2005"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0130","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1128\/AAC.01490-12","article-title":"Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths","volume":"57","author":"Hall","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0135","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jac\/dkm125","article-title":"Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit","volume":"60","author":"Nguyen","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0140","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ijantimicag.2011.07.008","article-title":"Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report","volume":"38","author":"Ngai","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0145","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1086\/424465","article-title":"Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity","volume":"190","author":"Wiederhold","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2011.01.004","article-title":"Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria","volume":"14","author":"Pfaller","year":"2011","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0155","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s10096-014-2069-z","article-title":"Assessment of caspofungin susceptibility of Candida glabrata by the Etest\u00ae, CLSI, and EUCAST methods, and detection of FKS1 and FKS2 mutations","volume":"33","author":"Bourgeois","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/JCM.01590-09","article-title":"Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp","volume":"48","author":"Pfaller","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0165","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1128\/AAC.01519-13","article-title":"Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0170","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijantimicag.2015.08.009","article-title":"Assessment of echinocandin regimens by pharmacokinetic\/pharmacodynamic analysis against Candida spp. In paediatric patients","volume":"46","author":"Xu","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0175","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1093\/jac\/dkv173","article-title":"Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis","volume":"70","author":"Grau","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0180","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13054-015-0758-3","article-title":"Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study","volume":"19","author":"Sinnollareddy","year":"2015","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2017.05.013_bib0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T00:31:56Z","timestamp":1602376316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917302066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0924857917302066"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.05.013","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dosing of caspofungin based on a pharmacokinetic\/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}